NASDAQ · JAGX
Healthcare · Biotechnology
$0.22
Down-$0.09 (-29.57%)
Updated Sep 16, 2026, 11:14 AM
SID Score
2.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
JAGX closed at $0.22 after 20 trading sessions, down 77.00% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $0.29 | $0.3015 | $0.1999 | $0.2246 | 2.13M |
| Sep 14, 2026 | $0.3098 | $0.3355 | $0.298 | $0.3189 | 451.68K |
| Sep 11, 2026 | $0.3255 | $0.3255 | $0.2916 | $0.314 | 410.82K |
| Sep 10, 2026 | $0.3669 | $0.3669 | $0.3096 | $0.319 | 759.18K |
| Sep 9, 2026 | $0.4251 | $0.4251 | $0.3251 | $0.3663 | 571.4K |
| Sep 8, 2026 | $0.5057 | $0.5057 | $0.40 | $0.4142 | 974.24K |
| Sep 4, 2026 | $0.677 | $0.6808 | $0.5716 | $0.5968 | 2.77M |
| Sep 3, 2026 | $0.766 | $0.766 | $0.6854 | $0.6944 | 141.82K |
| Sep 2, 2026 | $0.75 | $0.7559 | $0.709 | $0.7299 | 118.79K |
| Sep 1, 2026 | $0.795 | $0.825 | $0.7179 | $0.731 | 106.55K |
| Aug 31, 2026 | $0.7856 | $0.7998 | $0.7503 | $0.7911 | 48.22K |
| Aug 28, 2026 | $0.856 | $0.86 | $0.795 | $0.8099 | 160.6K |
| Aug 27, 2026 | $0.9799 | $0.9799 | $0.865 | $0.865 | 100.39K |
| Aug 26, 2026 | $0.93 | $1.03 | $0.902 | $0.9194 | 296.23K |
| Aug 25, 2026 | $0.91 | $0.9672 | $0.8651 | $0.9249 | 56.94K |
| Aug 24, 2026 | $0.89 | $1.0399 | $0.8399 | $0.912 | 259.2K |
| Aug 21, 2026 | $0.87 | $0.9279 | $0.8247 | $0.8675 | 76.62K |
| Aug 20, 2026 | $0.87 | $0.9098 | $0.8303 | $0.8735 | 71.87K |
| Aug 19, 2026 | $0.97 | $0.9802 | $0.8838 | $0.9243 | 230.47K |
| Aug 18, 2026 | $0.8516 | $1.03 | $0.81 | $0.9765 | 265.93K |
The latest Smart Investors Daily articles mentioning JAGX.
JAGX research
Company profile and research snapshot.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 19, 2025 | First Berlin | Buy | — |
| Jul 7, 2021 | Cantor Fitzgerald | Overweight | — |
| Nov 18, 2019 | H.C. Wainwright | Buy | — |
| Sep 12, 2019 | Ladenburg Thalmann | Buy | — |
| Jul 11, 2017 | Rodman & Renshaw | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 28, 2026
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool consistency and GI fluid balance
Benzinga · Jul 22, 2026
As announced, Napo has previously provided crofelemer powder for oral solution to treat select infant and pediatric IF patients with MVID in relevant expanded access programs in the U.S. under Single-Patient
Benzinga · Jul 17, 2026
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million. Barinthus Biotherapeutics (NASDAQ:BRNS)
Benzinga · Feb 18, 2026
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") today announced that its Board of Directors has declared a one-time special stock dividend (the "Special Stock Dividend") to holders of Jaguar Common Stock
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning JAGX.
